CD8A and non-small cell lung carcinoma: Although the current results based on the bTMB CTA did not support bTMB ≥16 as a standalone predictive biomarker in 1L immunotherapy of NSCLC, the utility of bTMB as a predictive biomarker may be improved when combined with other relevant biomarkers, such as genes for immune infiltration (CXCL9, CD8A, CD274 and CXCL13)10.